ESTRO 2024 - Abstract Book

S1863

Clinical - Mixed sites, palliation

ESTRO 2024

Conclusion:

There has been a surge in publications particularly in the past two years describing the use of SABR in oligoprogressive tumours. Promising results have been reported in prostate and kidney cancers mainly, with limited evidence in other sites including gastro-intestinal and breast tumours. There was observed variability in the definition and reporting of outcomes in studies examining SABR in OP disease. Moving forward, universal definitions and guidelines are strongly recommended to ensure consistency in reporting and comparability of future studies. A uniform definition such as proposed by ESTRO-EORTC appropriately stratifying patients into oligometastatic, oligoprogressive and oligorecurrence should be considered in future studies to allow for a better generalizability of the results.

Keywords: stereotactic, oligoprogression, metastasis

References:

[1] Iyengar P, Wardak Z, Gerber DE, Tumati V, Ahn C, Hughes RS, et al. Consolidative Radiotherapy for Limited Metastatic Non-Small-Cell Lung Cancer: A Phase 2 Randomized Clinical Trial. JAMA Oncol 2018;4:e173501. https://doi.org/10.1001/jamaoncol.2017.3501.